Extensive report on three "crowdfunding" initiatives, among them one led by
the company Iproteos, co-funded by researchers at IRB Barcelona.
Extensive article about the various research projects undertaken by Ernest Giralt’s group at IRB Barcelona. The article focuses on those devoted to the design of peptides with the capacity to cross the blood-brain barrier. “I think we are the only group worldwide studying the use of poisons as transporters of new drugs into the brain,” explains Ernest Giralt, full professor of the UB and coordinator of the Chemistry and Molecular Pharmacology Programme at IRB Barcelona.
Diario Médico reports on a study by Ernest Giralt’s lab (two pages) published in the Journal of Controlled Release on the design of a peptide capable of eliminating tumour cells. The peptide in question exploits the properties of wasp venom.
The company Iproteos, a spin-off from IRB Barcelona cofounded by Ernest Giralt and Teresa Tarragó, both researchers at IRB, has already surpassed 80% of the funding requested in a fundraising campaign that was launched in mid 2014. This news is echoed in El Periódico de Catalunya. The objective is to finance a drug for the treatment of schizophrenia.
Natàlia Carulla, associate researcher at IRB Barcelona devoted to studying
the aggregation of the protein beta-amyloid, which is strongly associated
with Alzheimer's disease, explains her approach to reveal the role of this
protein in this neurodegenerative disease, a condition that affects millions
of elderly people worldwide.
In a study recently published in ACS Chemical Biology, Carulla describes the
aggregation structures of beta-amyloid that are toxic for neurons.
The North American journal GEN reports on research performed by Natàlia Carulla, with the Peptides and Proteins Group at IRB, on beta-amyloid aggregates and their relation with Alzheimer’s disease. The study concludes that the most harmful aggregates for neurons are intermediate accumulations of beta-amyloid, these ranging from between 20 and 100 units.
IProteos, a spin-off from IRB Barcelona labs and co-funded by the researchers Teresa Tarragó and Ernest Giralt, has received the prize Expoquimia R+D+I for a new drug under development for the treatment of schizophrenia.
Catalan biotech Iproteos has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
The spin-off, founded by two IRB Barcelona scientists leaders in the field of therapeutic peptides, Teresa Tarrago and Ernest Giralt, expect to begin clinical trials of the compound in 2016.
Endowed with € 5,000 in each of their two categories -Biotechnology and Chemistry- the Expoquimia R+D+I Awards were delivered yesterday during the World Chemical Summit Night as part of the Expoquimia Exhibit at the Fair of Barcelona grounds.
Scientists at IRB Barcelona in collaboration with researchers at the University of Barcelona observe that aggregates of 20 to 100 units of beta-amyloid have a structure that is the most harmful to neurons.
This is the first time that a method allows scientists to monitor aggregation while simultaneously detect a structural pattern responsible for the toxicity of beta-amyloid aggregation.
The researchers state that these studies are a step towards finding a therapeutic target for a disease which, to date, has no treatment.
The Max-Bergmann-Society, a European-based organization of German, Swiss, and Austrian chemists, seeks to promote peptide research with a special emphasis on chemical methodologies.